Omeros’ (OMER) “Hold” Rating Reiterated at Needham & Company LLC

Omeros (NASDAQ:OMER)‘s stock had its “hold” rating restated by research analysts at Needham & Company LLC in a research note issued on Friday,Benzinga reports.

Other equities research analysts have also issued reports about the stock. RODMAN&RENSHAW upgraded shares of Omeros to a “strong-buy” rating in a report on Thursday, November 14th. D. Boral Capital reissued a “buy” rating and set a $36.00 price objective on shares of Omeros in a research report on Thursday. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, Rodman & Renshaw assumed coverage on Omeros in a research report on Thursday, November 14th. They issued a “buy” rating and a $9.00 target price for the company. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Stock Performance

Omeros stock opened at $9.18 on Friday. The stock has a market cap of $531.98 million, a P/E ratio of -3.97 and a beta of 2.01. The firm’s fifty day moving average price is $9.25 and its 200-day moving average price is $5.96. Omeros has a fifty-two week low of $2.61 and a fifty-two week high of $13.60.

Hedge Funds Weigh In On Omeros

A number of hedge funds have recently bought and sold shares of the business. Barclays PLC boosted its holdings in shares of Omeros by 121.3% during the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock valued at $376,000 after acquiring an additional 51,873 shares during the last quarter. State Street Corp boosted its stake in shares of Omeros by 0.3% during the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock worth $4,867,000 after acquiring an additional 3,839 shares during the last quarter. HighTower Advisors LLC boosted its stake in shares of Omeros by 7.2% during the 3rd quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock worth $235,000 after acquiring an additional 4,000 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Omeros by 0.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company’s stock valued at $5,318,000 after acquiring an additional 6,839 shares during the period. Finally, MML Investors Services LLC lifted its holdings in Omeros by 19.2% during the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 3,000 shares in the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.